First clinical evaluation of the QIAreachTM QuantiFERON-TB for tuberculosis infection and active pulmonary disease

The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection

“…(Petruccioli et al, 2016) Newer whole blood assays are now available with either read-out different from ELISA, as for the Liason QuantiFERON Plus based on the detection of IFN-γ by the chemiluminescence, or tests still based on ELISA as: Standard E TB-Feron (SD Biosensor, Republic of Korea), AdvanSure TB-IGRA ELISA (LG Chem, Republic of Korea) and LIOFeron TB/LTBI (LIONEX Diagnostics & Therapeutics GmbH, Braunschweig, Germany). (Fukushima et al, 2022;Hamada et al, 2021;Migliori et al, 2021;Miotto et al, 2022;Petruccioli et al, 2021) All these assays are based on tubes containing recombinant proteins or peptides from Mtb. Additionally, a whole blood test based on the detection of IFN-γ-induced protein-10 (IP-10) by ELISA (rBiopharm, Darmstadt, Germany) is now available.…”

QIAreach QuantiFERON-TB for the diagnosis ofMycobacterium tuberculosisinfection

“…The QIAreach® QuantiFERON-TB (QIAreach QFT; QIAGEN, Hilden, Germany) is a semi-automated assay that utilises a nanoparticle technology to measure the level of IFN-γ in plasma released by both CD4 and CD8 T-cells using the same TB2 tube of QTFplus. This new technology allows to detect TB infection using only a single blood collection tube (TB2), with single use cartridges (eStick) on a portable platform (eHub), capable of performing up to eight tests and providing a final qualitative result (positive or negative) within 20 min [ 11 , 12 ].…”

Know your tuberculosis epidemic–Is it time to add Mycobacterium tuberculosis immunoreactivity back into global surveillance?

“…Secondly, novel IGRA assays reduce the need for laboratory processing by using alternatives to enzyme-linked immunosorbent assays to measure interferon-gamma production (e.g. the QIAreach-QFT semi-automated lateral flow immunoassay) [52,53]. Novel assays aiming to measure recency of infection, persistence or risk of progression are not currently practical for large-scale screening [54][55][56][57].…”

“…Specific skin tests (such as C-Tb, Diaskintest and C-TST) have sensitivities of 75-91% in people with TB disease, high specificity amongst those at low risk of TB, and an agreement of 80-87% with IGRA [48,51]. Newer IGRA platforms, such as the QIAreach-QFT, appear promising but have not been evaluated in population-based studies [53]. There have been no direct head-to-head comparisons between the newer skin tests and newer interferon-gamma release assays, either with respect to their diagnostic performance or their feasibility and acceptability in practice.…”